What your patient might ask you…

Is there any new research for patients with dry AMD?

Thankfully, yes. Apellis Pharmaceuticals has started it’s phase 3 trial studying the effects of APL-2 for geographic atrophy.

Explain that more.
APL-2 is a synthetic cyclic peptide that works by “broadly blocking the complement cascade upstream.”

Give me fifteen seconds on the complement system.
The complement system is part of the immune system that promotes inflammation and attacks pathogens. The theory is that inflammation and the local activation of the complement system might play an important role in the pathogenesis of AMD.

Have they done other trials on APL-2?
Yes. Apellis recently released 18 month results of the FILLY trials where monthly intravitreal injections of APL-2 slowed progression of geographic atrophy lesion growth when compared with the sham.
Stay tuned.

Get in Touch


Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts